The Blood Test Rewriting Prenatal Care

Why the calmest pregnancy on paper isn’t always the whole story, and how a simple biomarker test is uncovering the invisible risk of preterm birth before any warning signs appear.
By Tiffany Inglis, MD, FACOG
Chief Medical Officer, Sera Prognostics
The first time you feel your baby move, everything else in the room goes quiet. You are 20 weeks along. Your bloodwork is normal, your blood pressure is fine, your anatomy scan looked beautiful, and your doctor smiled and said, “You are doing great.” You walk out to your car in the parking garage and cry a little, because the pregnancy is real now, and because “great” is the word you have been waiting to hear for months.
Then, a smaller thought slips in. What if there is something no one can see yet?
I have practiced obstetrics and supported Women’s Health for more than two decades, and I have sat with women in that exact moment. That uncertainty is an honest response to pregnancy, which is one of the most physically layered things a human body ever does. Most of the time, “you are doing great” turns out to be exactly right. Sometimes it does not, and the reason it does not is the piece that has bothered me most across my career.
The gap I could not stop thinking about
Preterm birth is what we call a delivery that happens before 37 weeks of pregnancy. It’s more common than people realize. In 2025, about 10.4% of babies born in the United States arrived too early, and that rate has barely moved in twenty years (Hamilton et al., 2026). Babies who come too soon are more likely to spend time in the neonatal intensive care unit, more likely to have trouble breathing or feeding, and more likely to face long-term challenges like learning differences, cerebral palsy, or chronic lung issues. The cost of care is real too. In one large national study of commercially insured families, medical spending in the first six months of life averaged about $76,000 per preterm infant, and for the earliest babies, those born as early as 24 weeks, it climbed to more than $600,000 per infant (Beam et al., 2020).
Here is the part that used to frustrate me clinically. For decades, the two pieces of information we relied on most to flag a pregnancy at risk of coming early were a previous preterm birth or a cervix that measured short on a second-trimester ultrasound. Both matter. Together they only catch a fraction of the women who will actually go on to deliver early. In fact, roughly 85% of preterm births before 37 weeks happen in women with no history of a prior preterm birth. And short cervix identifies only a small additional fraction of the risk (Biggio, 2024).
That is the invisible risk. A pregnancy can look perfectly typical on the outside while underlying biology tells a different story, and by the time symptoms show up, it is often too late for the preventive steps that work best. If you have ever wondered why a friend with a “textbook” pregnancy suddenly ended up with a baby in the NICU after an unexpected early delivery, that is usually why.
A quiet piece of information the body has been carrying all along
Every pregnancy is producing biological markers in the mother’s blood. Two of them, a pair of proteins called IGFBP4 and SHBG, tend to move in a particular direction in women who later experience spontaneous preterm birth (Saade et al., 2016). One is related to how well the placenta is delivering nutrients. The other seems to be part of the body’s response to inflammation at the placental interface. Neither is a symptom you can feel, and neither shows up on a scan until much later.
The PreTRM® Test, developed by Sera Prognostics, measures the ratio of these two proteins from a single blood draw taken between 18 to 21 weeks of pregnancy. That is it. Same visit, an easy finger prick, a few extra drops of blood. The result comes back as one of two things: higher risk for spontaneous preterm birth, or not higher risk. For most women, the result is not higher risk, that is genuinely good news, and no further action is needed beyond routine prenatal care. If you are one of the few who receive a higher risk result, you and your obstetrician have time to put a plan in place together. It may be simpler than you would expect. For many women, that pathway looks like a daily low-dose aspirin, vaginal progesterone at bedtime, and a weekly check in with a provider to see about how you are doing and feeling. Small, steady preventive steps, taken early, that give the pregnancy more of what it needs most: time.
Information that leads somewhere
A test is only useful if what it tells you can change what happens next. That is the question my colleagues in research have been chasing for the last decade, and the recent PRIME study is the answer I find most compelling. PRIME was a multicenter, randomized clinical trial of more than 5,000 pregnancies across 19 U.S. centers (Iriye et al., 2026). Every participant received the PreTRM Test between 18 to 21 weeks. Half of them had care guided by the result, and half received standard pregnancy care.
Women who tested higher risk in the test guided group were offered a simple, accessible bundle of preventive steps: daily vaginal progesterone, low-dose aspirin, and regular check-ins. Compared with standard care, that combination was associated with meaningfully fewer early preterm births, fewer NICU admissions, and fewer medical complications for babies as whole. The most striking finding, at least for me, was in the earliest deliveries. Screen-guided care was linked to a 56% reduction in births before 32 weeks, and in the trial no woman who started the intervention bundle by 24 weeks delivered before 32 weeks. Those are the pregnancies where every additional day inside the womb has the greatest impact on a baby’s future.
For first-time mothers, who by definition have no prior obstetric history to draw on, this kind of information can be especially valuable. In the PRIME first-pregnancy subgroup, screen-guided care reduced NICU admissions from 16.4% to 12.8% (a 22% reduction) (Sciscione et al., 2026).
What this feels like from the patient’s side
If you are eligible, the test itself is just another finger prick at your routine bloodwork appointment. Results come back to your obstetrician in about seven days. If the result is not higher risk, your prenatal visits will likely continue as planned and you have a little more peace of mind. If the result is higher risk, your doctor will walk you through the preventive options and decide together with you what makes sense for you. The test does not replace anything your obstetrician is already doing. It adds a critical piece of information to the conversation and supports prevention.
The PreTRM Test is designed for singleton pregnancies and is drawn during a specific window in the second trimester, so timing matters. It is specific to your blood levels in your current pregnancy, so each pregnancy can have a different result. It is not diagnostic, meaning it does not predict with certainty that preterm birth will happen. What it does is tell you whether the biology suggests a higher chance, so you and your care team can respond earlier rather than later. Talk to your obstetrician about whether it is right for you, and ask about coverage. If you would like to learn more or find out how to access the test, Anna Health is one place where eligible pregnant women can get information about how to get this test and stay informed.
Pregnancy is a strange mix of joy and vigilance, and I have never met a mother who did not carry both. The best gift we can give ourselves is the information to act earlier if something might go wrong, long before symptoms force our hand. For a long time, we did not have this early, objective information. Now, for many women, we do.
If you take one thing from this piece, let it be this: a calm scan and a clean chart are wonderful, and they are not the whole picture. Ask your obstetrician what they know about your risk of preterm birth, and ask whether PreTRM testing is right for you. For most, the result is a reassuring “you really are doing great.” That is worth knowing. And if it is not, you will have time on your side, a clear plan that works and allows a truly preventative care approach for you and your baby.
ABOUT THE AUTHOR

Tiffany Inglis, MD, FACOG, is Chief Medical Officer of Sera Prognostics and a board-certified obstetrician-gynecologist with more than 25 years of experience across direct patient care and the healthcare payer industry. At Sera, she leads clinical strategy across research and development, clinical operations, data science, and medical teams, making sure the company’s work is grounded in strong evidence and clear clinical value. Before Sera, Dr. Inglis was Chief Medical Officer at Carelon Health and held clinical leadership roles at Elevance Health, where she helped redesign the Women and Children’s Health portfolio. She earned her medical degree from the Medical College of Ohio and her bachelor’s in zoology, magna cum laude, from The Ohio State University, where she also played collegiate volleyball. Outside of work, she spends her time with her husband and two children.
LEARN MORE:



